Abiomed, Inc. (ABMD)
|Net Income (ttm)||200.47M|
|Trading Day||February 25|
|Day's Range||317.76 - 326.93|
|52-Week Range||119.01 - 387.40|
Investors searching for value opportunities may want to have a look at the three stocks listed below, as they represent equities in companies with high profitability and robust financial condi...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at upcoming investor conferences.
The market itself is sitting at lofty valuations, but several S&P 500 stocks are extremely overheated. Consider giving these 10 picks a little time to cool off.
Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.
It's not a vaccine company, a drugmaker, or a diagnostics company.
The study proves that Abiomed's (ABMD) Impella 5.5 with SmartAssist delivers successful clinical and device outcomes.
Large Clinical Study Presented at STS 2021 Finds 79% Survival Rate with Impella 5.5 with SmartAssist
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rat...
The company released its latest quarterly report.
Abiomed, Inc.'s (ABMD) CEO Michael Minogue on Q3 2021 Results - Earnings Call Transcript
ABIOMED's (ABMD) international Impella revenues improve in Q3.
Abiomed (ABMD) delivered earnings and revenue surprises of 1.74% and 2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Abiomed (NASDAQ:ABMD) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 20.54% year over year to $1.35, which beat the estimate of $1.13.
Abiomed Announces Q3 FY 2021 Record Revenue of $232 Million, up 5% Year Over Year, With 31% Operating Margin
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q3 fiscal year 2021 record revenue of $232 million, up 5% year over year with 31% operating margin.
The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the company will release financial results for the third quarter of fiscal 2021 on January 28, 2021.
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed's robust intellectu...
Abiomed's AAA financials, including a clean balance sheet and world-class margins can justify a premium in its valuation. Discounting Abiomed's future free cash flows, we derive the stock's in...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 39th annual J.P. Morgan Healthcare conference.
Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.
DANVERS, Mass.--(BUSINESS WIRE)--The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pu...
Biotech stocks simply can't match these reliable returns.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the Stephens Annual Investment Conference 2020.
It depends on whether or not the company's decelerating revenue growth is a symptom of larger problems.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Dr...
Revenue bounces back, but growth is still lacking.
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q2 2021 Results - Earnings Call Transcript
ABIOMED's (ABMD) international Impella revenues improved in Q2.
Abiomed (ABMD) delivered earnings and revenue surprises of 16.09% and 4.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Abiomed Announces Q2 FY 2021 Revenue of $210 Million, Up 27% Over Q1 FY 2021 and Up 2% Over Q2 FY 2020 With 29.2% Operating Margin
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q2 FY 2021 revenue of $210 million, up 27% over Q1 FY 2021 and up 2% over Q2 FY 2020 with 29.2% operating margin.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest ...
The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results
DANVERS, Mass.--(BUSINESS WIRE)--The U.S. FDA has granted Abiomed 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™.
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The stock price of Abiomed, a medical devices company best known for Impella, the world's smallest heart pump, is up roughly 60% since the beginning of this year, significantly outperforming t...
New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host a virtual meeting to discuss new clinical data presented at TCT Connect.
Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization with Impella Leads to Improved Outcomes
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and rep...
IART vs. ABMD: Which Stock Is the Better Value Option?
Look for proven resilience and growth prospects on the horizon.
Abiomed is definitely not cheap, but there is significant upside left in this stock.
This company's medical products can help patients suffering from COVID-19's most dangerous complications.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed will release financial results for the second quarter of fiscal 2021 on Thursday, October 29, 2020 at 8:00 a.m. ET.
Some countries, the U.S. in particular, are growing older - i.e. they have "aging populations.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the Raymond James North American Equities Conference.
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the 18th annual Morgan Stanley Global Healthcare Conference.
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?
Some of the names on this list may surprise you.
Abiomed engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are p... [Read more...]
|IPO Date |
Jul 29, 1987
|Stock Exchange |
|Ticker Symbol |
In 2019, Abiomed's revenue was $840.88 million, an increase of 9.29% compared to the previous year's $769.43 million. Earnings were $203.01 million, a decrease of -21.62%.
According to 9 analysts, the average rating for Abiomed stock is "Buy." The 12-month stock price forecast is 378.00, which is an increase of 18.51% from the latest price.